
Kimia Biosciences Ltd Downgraded to Sell Amid Financial and Technical Shifts
2026-06-04 08:07:12Kimia Biosciences Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 3 June 2026, reflecting deteriorating financial performance and mixed technical signals. Despite a modest uptick in daily share price, the company faces significant challenges across quality, valuation, financial trends, and technical indicators, prompting a reassessment of its market standing within the Pharmaceuticals & Biotechnology sector.
Read full news article
Golden Cross Forms in Kimia Biosciences Ltd — On a Day the Stock Fell 1.35%. What the Mixed Signals Mean
2026-06-02 18:20:06The 50-day moving average has crossed above the 200-day moving average for Kimia Biosciences Ltd, signalling a golden cross on 2 Jun 2026. Yet, the stock declined 1.35% on the same day, while monthly technical indicators remain bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability.
Read full news articleAre Kimia Biosciences Ltd latest results good or bad?
2026-05-30 19:39:08Kimia Biosciences Ltd's latest financial results for Q4 FY26 indicate significant operational challenges. The company reported net sales of ₹27.20 crores, reflecting a 9.63% decline from the previous quarter and a more substantial 28.87% decrease year-on-year. This revenue contraction is accompanied by a sharp drop in net profit, which fell to ₹0.37 crores, marking a 93.20% decline compared to the prior quarter and an 81.41% decrease year-on-year. The profit after tax (PAT) margin has compressed to 1.36%, down from 5.20% in the same quarter last year, while the operating margin also deteriorated from 21.39% to 9.82%. These figures suggest that the company is experiencing severe pricing pressures or cost management issues. Additionally, the effective tax rate of 78.98% raises concerns about the sustainability of the company's tax position and may indicate one-time adjustments impacting the bottom line. Fo...
Read full news article
Kimia Biosciences Q4 FY26: Profit Plunges 81% as Margins Collapse Despite Revenue Resilience
2026-05-29 23:46:47Kimia Biosciences Ltd., a micro-cap pharmaceutical company specialising in bulk drug manufacturing, reported a dramatic 81.41% quarter-on-quarter decline in net profit for Q4 FY26, posting ₹0.37 crores compared to ₹1.99 crores in Q4 FY25. The sharp earnings contraction occurred despite relatively stable revenue performance, with net sales declining 28.87% year-on-year to ₹27.20 crores. The stock, currently trading at ₹36.50 with a market capitalisation of ₹168.00 crores, has struggled over the past year, delivering negative returns of 27.01% whilst the broader pharmaceuticals sector gained 9.25%.
Read full news article
Kimia Biosciences Ltd is Rated Sell
2026-05-24 10:10:37Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleWhen is the next results date for Kimia Biosciences Ltd?
2026-05-21 23:17:41The next results date for Kimia Biosciences Ltd is scheduled for 29 May 2026....
Read full news article
Kimia Biosciences Ltd is Rated Sell
2026-05-13 10:11:11Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Kimia Biosciences Ltd is Rated Sell
2026-05-02 10:10:38Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read full news article
Kimia Biosciences Ltd is Rated Sell
2026-04-21 10:10:52Kimia Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news articleAnnouncement under Regulation 30 (LODR)-Newspaper Publication
01-Jun-2026 | Source : BSEPublication of Results for quarter and year ended March 31 2026
Outcome Of The Board Meeting Held On 29 May 2026
29-May-2026 | Source : BSEApproval of Audited standalone Financial results alongwith Audited Report thereon for financial year 2025-26
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations 2015
20-May-2026 | Source : BSEKimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve the Audited Financial Results (Standalone ) for the quarter and financial year ended 31st March 2026 along with the Audit Report thereon
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






